±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 846  |  »Ø¸´: 6
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
¡¾Óн±½»Á÷¡¿»ý¼«»Ø¸´±¾Ìû×Ó£¬²ÎÓë½»Á÷£¬¾ÍÓлú»á·ÖµÃ×÷Õß a1001 µÄ 50 ¸ö½ð±Ò

a1001

½ð³æ (СÓÐÃûÆø)

cpu

[½»Á÷] ¡¾ÇóÖú¡¿ÄÄλÄܰïæ²é¸öUSP33ÉϵÄÒ©Îï

ÄÄλÄܰïæ²é¸öUSP33ÉϵÄÒ©Î
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

nkbeholder

ľ³æ (ÕýʽдÊÖ)

ÍøÉÏÓУ¬×Ô¼ºÏÂÒ»±¾¡£
2Â¥2010-03-03 14:56:35
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

houhou1986

½ð³æ (ÕýʽдÊÖ)

¡ï
±¿±¿Öí0608(½ð±Ò+1):лл²ÎÓë 2010-03-04 08:31
http://ishare.iask.sina.com.cn/f/6297627.html

È¥ÕâÀï¿´¿´USP33-NF28×ÜÂÛ²¿·Ö
3Â¥2010-03-04 01:01:25
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

×ÏÜÔÀò

½ð³æ (СÓÐÃûÆø)

Çë½Ì3Â¥Ò»¸öÎÊÌ⣬ÎÒ°´ÕÕÄãµÄʹÓÃÖ¸ÄÏÀïÃæ½²µÄ×öÁË£¬µ«ÊÇË«»÷USP33NF28µ¯³ö³ÌÐòÒѹýÆÚ£¬²»ÖªµÀÊÇʲôԭÒò°¡£¿
4Â¥2010-03-04 08:52:35
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
ÄãÒª²éʲôҩÎï°¡£¿
5Â¥2010-03-04 09:40:47
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

a1001

½ð³æ (СÓÐÃûÆø)

cpu

atorvastatin calcium
6Â¥2010-03-13 10:30:38
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

gubangjin

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

Ïë×Ô¼º¸ÉµãʵÄÈË

Monograph Number:  0000864
Title:  Atorvastatin
CAS Registry Number:  134523-00-5
CAS Name:  (bR,dR)-2-(4-Fluorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
Molecular Formula:  C33H35FN2O5
Molecular Weight:  558.64
Percent Composition:  C 70.95%, H 6.31%, F 3.40%, N 5.01%, O 14.32%
Literature References:  HMG-CoA reductase inhibitor.  Prepn:  B. D. Roth, EP 409281; idem, US 5273995 (1991, 1993 both to Warner-Lambert); K. L. Baumann et al., Tetrahedron Lett. 33, 2283 (1992).  Solubility and kinetic studies:  A. S. Kearney et al., Pharm. Res. 10, 1461 (1993).  LC/MS/MS determn in serum:  M. Jemal et al., Rapid Commun. Mass Spectrom. 13, 1003 (1999).  Clinical pharmacokinetics:  D. D. Cilla, Jr. et al., Clin. Pharmacol. Ther. 60, 687 (1996).  Review of pharmacology and clinical experience:  H. S. Yee, N. T. Fong, Ann. Pharmacother. 32, 1030-1043 (1998); of efficacy in diabetic patients:  K. F. Croom, G. L. Plosker, Drugs 65, 137-152 (2005).

Derivative Type:  Calcium salt trihydrate
CAS Registry Number:  344423-98-9;  134523-03-8 (anhydrous)
Manufacturers' Codes:  CI-981
Trademarks:  Lipitor (Parke-Davis);  Sortis (Pfizer);  Torvast (Pfizer);  Totalip (Guidotti)
Molecular Formula:  C66H68CaF2N4O10.3H2O
Molecular Weight:  1209.39
Percent Composition:  C 65.55%, H 6.17%, Ca 3.31%, F 3.14%, N 4.63%, O 17.20%
Properties:  White to off-white crystalline powder.  [a]D -7.4¡ã (c = 1 in DMSO).  Freely sol in methanol; slightly sol in ethanol; very slightly sol in acetonitrile, distilled water, phosphate buffer (pH 7.4).  Insol in aq solns of pH 4 and below.
Optical Rotation:  [a]D -7.4¡ã (c = 1 in DMSO)

Derivative Type:  Sodium salt
CAS Registry Number:  134523-01-6
Molecular Formula:  C33H34FN2NaO5
Molecular Weight:  580.62
Percent Composition:  C 68.26%, H 5.90%, F 3.27%, N 4.82%, Na 3.96%, O 13.78%
Properties:  pKa 4.46.  Soly in water (30¡ã):  20.4 mg/ml (pH 2.1); 1.23 mg/ml (pH 6.0).
pKa:  pKa 4.46
Derivative Type:  Lactone
CAS Registry Number:  125995-03-1
CAS Name:  5-(4-Fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1H-pyrrole-3-carboxamide
Molecular Formula:  C33H33FN2O4
Molecular Weight:  540.62
Percent Composition:  C 73.31%, H 6.15%, F 3.51%, N 5.18%, O 11.84%
Properties:  mp 159.2-160.7¡ã.  [a]D +26.05¡ã (c = 1 in chloroform).
Melting point:  mp 159.2-160.7¡ã
Optical Rotation:  [a]D +26.05¡ã (c = 1 in chloroform)

Therap-Cat:  Antilipemic.
Keywords:  Antilipemic; HMG CoA Reductase Inhibitors; HMG CoA Reductase Inhibitor.
ÍøÊÂÒÑËæ·ç¶øÈ¥!
7Â¥2010-03-14 22:24:20
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ a1001 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0856Çóµ÷¼Á +7 —öèñ 2026-03-28 7/350 2026-03-29 08:28 by fmesaito
[¿¼ÑÐ] 085600£¬×¨Òµ¿Î»¯¹¤Ô­Àí£¬321·ÖÇóµ÷¼Á +4 ´ó²öС×Ó 2026-03-28 4/200 2026-03-29 00:32 by 544594351
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤272Çóµ÷¼Á +9 °¢Ë¹µÙ·Ò2004 2026-03-28 9/450 2026-03-28 15:21 by 1018329917
[¿¼ÑÐ] ҩѧ105500Çóµ÷¼Á +3 Ssun¡£¡£ 2026-03-28 3/150 2026-03-28 11:24 by lxf170613
[¿¼ÑÐ] ¡¾Çóµ÷¼Á¡¿085601²ÄÁϹ¤³Ìר˶ | ×Ü·Ö272 | +6 ½Å»¬µÄÊØ·¨¹«Ãñ 2026-03-27 6/300 2026-03-28 11:02 by gjlllb
[¿¼ÑÐ] 292Çóµ÷¼Á +14 ¶ì¶ì¶ì¶î¶î¶î¶î¶ 2026-03-25 15/750 2026-03-28 08:45 by WYUMater
[¿¼ÑÐ] 085404Çóµ÷¼Á£¬×Ü·Ö309£¬±¾¿Æ¾­Àú½ÏΪ·á¸» +4 À´²Æaa 2026-03-25 4/200 2026-03-28 07:41 by °ô°ôÇòÊÖ
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤µ÷¼Á +10 A-¶ßÀ²ZÃÎ 2026-03-23 16/800 2026-03-27 15:13 by caszguilin
[¿¼ÑÐ] »¯Ñ§308·ÖÇóµ÷¼Á +8 ÄãºÃÃ÷ÌìÄãºÃ 2026-03-23 9/450 2026-03-27 14:01 by Ñî¹âÓÚÇàÔÆ
[¿¼ÑÐ] 322Çóµ÷¼Á +4 ÎÒÕæµÄºÜÏëѧϰ 2026-03-23 4/200 2026-03-27 13:51 by ÑîÑîÑî×Ï
[¿¼ÑÐ] Çóµ÷¼Á +3 Áõ¿Â@ 2026-03-24 4/200 2026-03-27 11:28 by shangxh
[¿¼ÑÐ] 315µ÷¼Á +4 0860Çóµ÷¼Á 2026-03-26 5/250 2026-03-27 11:23 by wangjy2002
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸ ÄϾ©º½¿Õº½Ìì´óѧ´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶ +4 @taotao 2026-03-26 5/250 2026-03-27 08:10 by hypershenger
[¿¼ÑÐ] 325Çóµ÷¼Á +3 Aoyijiang 2026-03-23 3/150 2026-03-26 20:46 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤304ÇóBÇøµ÷¼Á +3 Çñgl 2026-03-26 6/300 2026-03-26 18:03 by Çñgl
[¿¼ÑÐ] ×Ü·Ö293Çóµ÷¼Á +6 ¼ÓÒ»Ò»¾Å 2026-03-25 8/400 2026-03-26 13:30 by yujianx
[¿¼ÑÐ] 332Çóµ÷¼Á +6 032500 2026-03-25 6/300 2026-03-25 22:45 by 418490947
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϺ½²ÄÁÏר317·ÖÇóµ÷¼Á +5 ըѽըѽըÊíÌõ 2026-03-23 5/250 2026-03-24 16:52 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 284Çóµ÷¼Á +3 yanzhixue111 2026-03-23 6/300 2026-03-23 22:58 by pswait
[¿¼ÑÐ] 361Çóµ÷¼Á +3 Glack 2026-03-22 3/150 2026-03-23 22:03 by fuyu_
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û